Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia(2024)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
维普
万方数据
急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是最常见的急性白血病之一,发病急、进展快,化疗和移植的规范化应用已极大改善患者预后,但仍存在未满足的治疗需求.近年以双特异性T细胞衔接器(Bispecific T cell Engager,BiTE)为代表的免疫治疗发展迅速,为ALL治疗提供了更多选择,同时也对临床诊疗管理提出了更高的要求.专家组基于国内外最新循证医学证据、相关指南和临床实践,对2022年版《双特异性T细胞衔接器治疗急性淋巴细胞白血病指导原则》进行更新,制定了该版中国专家共识.
Acute lymphoblastic leukemia(ALL)is one of the most common acute leukemias,with rapid onset and progression.The standardized application of chemotherapy and transplantation have im-proved the prognosis of patients,while the unmet therapeutic needs still exist.Recently novel immunothera-pies including Bispecific T cell Engager develop rapidly,offering more options for ALL treatment and also demanding higher requirements for clinical diagnosis and treatment management.Based on the evidence of domestic and international medical evidence and clinical experience,the expert panel updated Chinese con-sensus for the Bispeific T cell Engager in the treatment of B-cell acute lymphoblastic leukemia(2022)and formulated this edition of the Chinese expert consensus.
Leukemia,lymphoblastic,acuteBispecific T cell engagerImmunotherapies
维普
万方数据
